

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/44, C07D 471/04	A1	(11) International Publication Number: WO 99/30710 (43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/US98/25920 (22) International Filing Date: 7 December 1998 (07.12.98) (30) Priority Data: 60/069,633 13 December 1997 (13.12.97) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US). (72) Inventors: MISRA, Raj, N.; 12 Eaton Place, Hopewell, NJ 08525 (US). KIMBALL, S., David; 13 Charred Oak Lane, East Windsor, NJ 08520 (US). RAWLINS, David, B.; 219 Vernon Road, Morrisville, PA 19067 (US). WEBSTER, Kevin, R.; 804 Roelofs Road, Yardley, PA 19067 (US). BURSUKER, Isia; 29 Currier Way, Cheshire, CT 06410 (US). (74) Agents: MARENBERG, Barry, J. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS**(57) Abstract**

Compounds of formula (I) and pharmaceutically acceptable salts thereof for use as inhibitors of cyclin dependent kinases, wherein: X is O, S(O)_m; Y is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl; R₁ is hydrogen or lower alkyl; R₂ is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-alkyl, -O-aryl, -NR₄R₅; R₃ is hydrogen or lower alkyl; R₄ is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-alkyl, -O-aryl; R₅ is hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, -O-alkyl, -O-aryl; and m is 0, 1 or 2. The compounds of formula (I) are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.



(I)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS

5

Brief Description of the Invention

The present invention is directed to the use of compounds of the formula



10

and pharmaceutically acceptable salts thereof as inhibitors of cyclin dependent kinases. As used in formula I, and throughout the specification, the symbols have the following meanings:

15

X is O, S(O)_m;

Y is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl;

R₁ is hydrogen or lower alkyl;

R₂ is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-alkyl, -O-aryl, -NR₄R₅;

20

R₃ is hydrogen or lower alkyl;

R₄ is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl,

25

heterocycloalkylalkyl, -O-alkyl, -O-aryl;

R₅ is hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, -O-alkyl, -O-aryl; and

m is 0, 1 or 2.

30

The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.

Description of the Invention

The present invention provides for a method of using compounds of formula I as inhibitors of cyclin dependent kinases, which are active in the treatment of proliferative diseases, such as for example, but not limited to, cancer, Alzheimer's disease, arthritis, inflammation, and cardiovascular disease. The present invention also contemplates pharmaceutical compositions employing such compounds.

Listed below are definitions of various terms used to describe the compounds of the instant invention. These definitions apply to the terms as they are used throughout the specification (unless they are otherwise limited in specific instances) either individually or as part of a larger group.

It should be noted that any heteroatom with unsatisfied valances is assumed to have the hydrogen atom to satisfy the valances.

Carboxylate anion refers to a negatively charged group -COO^- .

The term "alkyl" or "alk" refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 12 carbon atoms unless otherwise defined. The term "lower alkyl" refers to an alkyl group of 1 to 6 carbon atoms. An alkyl group is an optionally substituted straight, branched or cyclic saturated hydrocarbon group. When substituted, alkyl groups may be substituted with up to four substituent groups, R as defined, at any available point of attachment. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group". Exemplary unsubstituted such groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like. Exemplary

substituents may include but are not limited to one or more of the following groups: halo (such as F, Cl, Br, I), haloalkyl (such as CCl_3 or CF_3), alkoxy, aryloxy, alkyl $\text{S}(\text{O})_m$ ($m = 0, 1, 2$), aryl $\text{S}(\text{O})_m$ ($m = 0, 1, 2$) hydroxy, carboxy ($-\text{COOH}$), alkyloxycarbonyl ($-\text{COOR}'$), alkylcarbonyloxy
5 ($-\text{OCOR}'$), amino ($-\text{NH}_2$),
quaternary nitrogen, carbamoyl ($-\text{NHCOOR}'$ - or $-\text{OCONHR}'$ -), urea ($-\text{NHCONHR}'$ -), thiol ($-\text{SH}$), cyano or nitro. Alkyl groups as defined may also comprise one or more carbon to carbon double bonds or one or more carbon to carbon triple bonds.

10 The term "alkenyl" refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one carbon to carbon double bond.

The term "alkynyl" refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 12 carbon atoms and at least one
15 carbon to carbon triple bond.

Cycloalkyl is a type of alkyl containing from 3 to 15 carbon atom, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings. Exemplary unsubstituted such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. Exemplary
20 substituents include one or more of the following groups: halogen, alkyl, alkoxy, alkyl, hydroxy, amino, nitro, cyano, thiol and/or alkylthio.

The terms "alkoxy" or "alkylthio", as used herein, denote an alkyl group as described above bonded through an oxygen linkage ($-\text{O}-$) or a sulfur linkage ($-\text{S}-$), respectively.

25 The term "alkyloxycarbonyl", as used herein, denotes an alkoxy group bonded through a carbonyl group. An alkoxy carbonyl radical is represented by the formula: $-\text{C}(\text{O})\text{OR}$, where the R group is a straight or branched C_{1-6} alkyl group.

The term "alkylcarbonyl" refers to an alkyl group bonded through
30 a carbonyl group.

The term "alkylcarbonyloxy", as used herein, denotes an alkylcarbonyl group which is bonded through an oxygen linkage.

The term "arylalkyl", as used herein, denotes an aromatic ring bonded through an alkyl group as described above.

The term "aryl" refers to monocyclic or bicyclic aromatic rings, e.g. phenyl, substituted phenyl and the like, as well as groups which are fused, e.g., naphthyl, phenanthrenyl and the like. An aryl group thus contains at least one ring having at least 6 atoms, with up to five such rings being present, containing up to 22 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms. Aryl groups may optionally be substituted with one or more groups including, but not limited to halogen, alkyl, alkoxy, hydroxy, carboxy, carbamoyl, alkyloxycarbonyl, nitro, trifluoromethyl, amino, cycloalkyl, cyano, alkylS(O)_m (m = 0, 1, 2), or thiol.

The term "heteroaryl" refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S, or N, in which a carbon or nitrogen atom is the point of attachment, and in which one or two additional carbon atoms is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms, said heteroaryl group being optionally substituted as described herein. Additional nitrogen atoms may be present together with the first nitrogen and oxygen or sulfur. Exemplary heteroaryl groups include the following: thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrrolidinyl, piperidinyl, thiazolyl, oxazolyl, triazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinal, triazinylazepinyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, benzofurazanyl and tetrahydropyranyl. Exemplary substituents include one or more of the following: halo, alkyl, alkoxy, hydroxy, cycloalkyl, nitro, cyano, amino, alkylS(O)_m (m=0, 1, 2), or thiol. The term "heteroarylalkyl", as used herein denotes a heteroaryl ring bonded through an alkyl group as described hereinabove.

The term "heteroarylium" refers to heteroaryl groups bearing a quaternary nitrogen atom and thus a positive charge.

The term "heterocycloalkyl" refers to a cycloalkyl group (nonaromatic) in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S or N, and in which up to three additional carbon atoms may be replaced by said heteroatoms. In
5 addition, the sulfur may be oxidated to the sulfone (-SO₂-) or sulfoxide (-SO-) and the nitrogen may be quaternary.

The term "quaternary nitrogen" refers to a tetravalent positively charged nitrogen atom including, e.g. the positively charged nitrogen in a tetraalkylammonium group (e.g. tetramethylammonium,
10 N-methylpyridinium), the positively charged nitrogen in protonated ammonium species (e.g. trimethylhydroammonium, N-hydropyridinium), the positively charged nitrogen in amine N-oxides (e.g. N-methyl-morpholine-N-oxide, pyridine -N-oxide), and the positively charged nitrogen in an N-amino-ammonium group (e.g.
15 N-aminopyridinium).

The term "heteroatom" means O, S, P or N, selected on an independent basis.

The term "halogen" or "halo" refers to chlorine, bromine, fluorine, iodine.

20 The term "PMB" refers to para-methoxybenzyl.

When a functional group is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site. Suitable protecting groups for the compounds of the present invention will be recognized from the present application taking
25 into account the level of skill in the art, and with reference to standard textbooks, such as Greene, T. W. et al., *Protective Groups in Organic Synthesis*, Wiley, N.Y. (1991).

Suitable examples of salts of the compounds according to the invention with inorganic or organic acids are hydrochloride,
30 hydrobromide, sulfate, phosphate. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds I or their pharmaceutically acceptable salts, are also included.

All stereoisomers of the compounds of the instant invention are
35 contemplated, either in admixture or in pure or substantially pure form. The definition of the compounds according to the invention embraces all


possible stereoisomers and their mixtures. It very particularly embraces the racemic forms and the isolated optical isomers having the specified activity. The racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or
5 crystallization of diastereomeric derivatives or separation by chiral column chromatography. The individual optical isomers can be obtained from the racemates by conventional methods, such as, for example, salt formation with an optically active acid followed by crystallization.

10 It should be understood that the present invention includes prodrug forms of the compounds of formula I. Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:


- 15 (a) Design of Prodrugs, edited by H. Bundgaard (Elsevier, 1985); and Methods in Enzymology, Vol. 42, pp. 309-396, edited by K. Widder et al., (Academic Press, 1985);
- (b) A Textbook of Drug Design and Development, edited by Krosgaard-Larsen and H. Bundgaard, Chapter 5, "Design and Application of
20 Prodrugs," by H. Bundgaard, pp. 113-191 (1991);
- (c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, pp. 1-38 (1992);
- (d) H. Bundgaard et al., Journal of Pharmaceutical
25 Sciences, 77, 285 (1988); and
- (e) N. Kayeka et al., Chem. Phar. Bull., 32, 692 (1984).

It should be understood that solvates (e.g. hydrates) of the compounds of formula I are also within the scope of the present
30 invention. Methods of solvation are generally known in the art. Accordingly, the compounds of the instant invention may be in the free or hydrate form, and may be obtained by methods exemplified by the following schemes.


Compounds of formula I for use as inhibitors of cyclin dependent
35 kinases can be prepared by reacting a compound of formula




with a base such as sodium hydroxide or sodium carbonate to give a free base of formula



Compound IIa is reacted with a compound of formula




at 130° under reduced pressure to obtain compounds of formula



The starting compound of formula II, where R₁ is hydrogen is easily prepared by reacting acrylonitrile with hydrazine hydrate in a solvent such as THF, followed by addition of p-methoxybenzaldehyde. The compound which results from this reaction is then reacted with a mixture of sodium n-butoxide in n-butanol followed by HCl to provide the key early intermediate of compound II.


Compounds of formula IV are then reacted at a temperature from 220° to 260° in diphenyl ether to obtain a compound of formula



5


Compound V is then reacted with phosphorous oxychloride at a temperature from 25° to 130° to yield a compound of formula

10



Compound VI is reacted with an alkoxide such as sodium n-butoxide in n-butanol at a temperature from 25° to 90°, and then water is added to form a compound of formula

15




20


wherein an n-butoxy group is added to the 4 carbon, such that X of formula I is oxygen and Y is an n-butyl lower alkyl group.

Compound VII is then reacted with a mixture of oxalyl chloride and catalytic DMF in an inert solvent such as dichloromethane followed by N,O-dimethylhydroxylamine hydrochloride and an amine base, such as triethylamine, to provide compounds of formula

25




Compounds of formula VIII are then reacted with an acid, such as trifluoroacetic acid (TFA), at a temperature from 25° to 90°, or hydrogen in the presence of a catalyst, such as palladium on carbon, to provide compounds of formula



10


Compounds of formula IX are then reacted with an excess of an organometallic reagent such as an organolithium (2-15 eq) in THF or ether to provide compounds of formula I where X is oxygen and R₂ is alkyl or aryl.

Compound VII may alternatively be reacted with a chlorinating agent, such as oxalyl chloride, and catalytic DMF in an inert solvent such as dichloromethane to afford compounds of the formula



20


Compounds of formula X are then reacted with an organometallic reagent such as an organolithium (0.70-1.5 eq.) in THF or ether at a temperature from -90° to -20° to give compounds of the formula



(XI)


Compounds of the formula XI are then reacted with an acid, such as TFA, or hydrogen in the presence of a catalyst, such as palladium on carbon to give compounds of formula I where X is oxygen and R₂ is not -O-alkyl, -O-aryl, or -NR₄R₅.

In another alternative scheme, compound VII may be reacted with oxalyl chloride and catalytic DMF followed by R₄R₅NH and triethylamine in an inert solvent such as dichloromethane to provide the compound of formula



(XII)


Compound XII is then reacted with TFA at a temperature from 25° to 90° to obtain compounds of the formula




(XIII)

An alternative synthesis of compounds of formula I where R₂ is aryl or heteroaryl is exemplified by compound XIV below, where in formula I R₁ is hydrogen, R₂ is phenyl, and R₃ is hydrogen.


A compound of formula XIV



5 may be prepared by reacting compound IIa with a compound of the formula




10 to provide compounds of the formula




15 Compound XV may be prepared by reacting ethylbenzoyl acetate with triethylorthoformate in a solution of acetic anhydride at a temperature from 100 to 145°.

The compound of formula XVI is then added to diphenyl ether heated to a temperature from 220° to 260° to provide a compound of the formula


20



25 Compound XVII is then reacted with phosphorous oxychloride at a temperature from 25° to 130° to provide a compound of the formula



- 5 which is then reacted with a Y-XNa such that the nucleophilic X is substituted for the chlorine on the 4 carbon to provide compounds of the formula




10

wherein X is oxygen or sulfur. Reaction in TFA at a temperature from 25° to 90° removes the PMB-protecting group to provide compound XIV, when Y is not CH₂Ph.


- 15 Alternatively, reacting compound XIV, when X is oxygen or sulfur and Y is hydrogen, with benzylbromide in the presence of sodium bicarbonate results in the addition of a benzyl group to X.

Compounds of formula XIV, where X is sulfoxide or sulfone may be prepared from compound of formula

20



according to the following reaction schemes:



Intermediates of this invention may also be prepared by processes disclosed in U.S. Patent Nos. 3,828,057, 3,966,746, 3,979,399, and 3,985,757 which are incorporated by reference herein. More specifically, intermediates of formula II may be prepared by procedures described in Hoehn, H., Z. Chem. 10, pp. 386-388 (1970). Intermediates of formula I, where X is oxygen and Y is hydrogen may be prepared as described in Denzel, T., and Hoehn, H. Arch. Chem. 309, pp. 486-503 (1976).

Compounds of formula II and III are commercially available or may be prepared by methods known to one of ordinary skill in the art.

All other compounds may be prepared by modification of the procedures described herein.

The preferred compounds of formula I are those where:

- R₁ is hydrogen;
- R₂ is aryl or heteroaryl;
- R₃ is hydrogen;
- X is oxygen; and
- Y is alkyl, cycloalkyl or cycloalkylalkyl;

The most preferred compounds of formula I are those where:

- R₁ is hydrogen;
- R₂ is 4-bromo-2,6-difluorophenyl, 4-chloro-2,6-difluorophenyl, or 2,4,6-trifluorophenyl;
- R₃ is hydrogen;
- X is oxygen; and

Y is lower alkyl.

The compounds according to the invention have pharmacological properties; in particular, the compounds of formula I are inhibitors of protein kinases such as the cyclin dependent kinases (cdks), for example, cdc2 (cdk1), cdk2, and cdk4. The novel compounds of formula I are expected to be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurodegenerative disorders and cardiovascular disease.

More specifically, the compounds of formula I are useful in the treatment of a variety of cancers, including (but not limited to) the following:

-carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;

-hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;

-hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia;

-tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma;

- tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and

-other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratocanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Due to the key role of cdk5 in the regulation of cellular proliferation in general, inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostate
5 hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.

10 Compounds of formula I may also be useful in the treatment of Alzheimer's disease, as suggested by the recent finding that cdk5 is involved in the phosphorylation of tau protein (*J. Biochem*, 117, 741-749 (1995)).

Compounds of formula I may induce or inhibit apoptosis. The
15 apoptotic response is aberrant in a variety of human diseases. Compounds of formula I, as modulators of apoptosis, will be useful in the treatment of cancer (including but not limited to those types mentioned hereinabove), viral infections (including but not limited to herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and
20 adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus), neurodegenerative disorders (including
25 but not limited to Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia,
30 atherosclerosis, toxin-induced or alcohol related liver diseases, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including but not limited to osteoporosis and arthritis) aspirin-sensitive

rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.

Compounds of formula I, as inhibitors of the cdks, can modulate the level of cellular RNA and DNA synthesis. These agents would
5 therefore be useful in the treatment of viral infections (including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus).

Compounds of formula I may also be useful in the chemoprevention of cancer. Chemoprevention is defined as inhibiting
10 the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.

Compounds of formula I may also be useful in inhibiting tumor angiogenesis and metastasis.

15 Compounds of formula I may also act as inhibitors of other protein kinases, e.g., protein kinase C, her2, raf 1, MEK1, MAP kinase, EGF receptor, PDGF receptor, IGF receptor, PI3 kinase, weel kinase, Src, Abl and thus be effective in the treatment of diseases associated with other protein kinases.

20 The compounds of this invention may also be useful in combination (administered together or sequentially) with known anti-cancer treatments such as radiation therapy or with cytostatic or cytotoxic agents, such as for example, but not limited to, DNA interactive agents, such as cisplatin or doxorubicin; topoisomerase II inhibitors,
25 such as etoposide; topoisomerase I inhibitors such as CPT-11 or topotecan; tubulin interacting agents, such as paclitaxel, docetaxel or the epothilones; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors, such as 5-fluorouracil; and anti-metabolites, such as methotrexate.

30 If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent or treatment within its approved dosage range. For example, the cdc2 inhibitor olomucine has been found to act synergistically with known

cytotoxic agents in inducing apoptosis (*J. Cell Sci.*, 108, 2897 (1995)).

Compounds of formula I may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of

5 administration; compounds of formula I may be administered either prior to or after administration of the known anticancer or cytotoxic agent. For example, the cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of administration with anticancer agents. *Cancer Research*, 57, 3375 (1997).

10 The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological assays. The exemplified pharmacological assays which follow have been carried out with the compounds according to the invention and their salts. The compounds of examples 1 to 8 exhibited cdc2/cyclin B1 kinase activity
15 with IC₅₀ values less than 50 μ M. The compounds of examples 1 to 8 exhibited cdk2/cyclin E kinase activity with IC₅₀ values less than 50 μ M. The compounds of examples 1 to 8 exhibited cdk4/cyclin D1 kinase activity with IC₅₀ values less than 50 μ M.

20 cdc2/cyclin B1 Kinase Assay

The activity of cdc2/cyclin B1 kinase was determined by monitoring the incorporation of ³²P into histone H1. The reaction consisted of 50 ng baculovirus expressed GST-cdc2, 75 ng baculovirus expressed GST-cyclin B1, 1 μ g histone H1 (Boehringer Mannheim), 0.2
25 mCi of ³²P g-ATP and 25 mM ATP in kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl₂, 1 mM EGTA, 0.5 mM DTT). The reaction was incubated at 30°C for 30 minutes and then stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15% and incubated on ice for 20 minutes. The reaction was harvested onto GF/C unfilter
30 plates (Packard) using a Packard Filtermate Universal harvester, and the filters were counted on a Packard TopCount 96-well liquid scintillation counter (Marshak, D.R., Vanderberg, M.T., Bae, Y.S., Yu,

I.J., *J. of Cellular Biochemistry*, 45, 391-400 (1991), incorporated by reference herein).

cdk2/cyclin E Kinase Assay

5 The activity of cdk2/cyclin E kinase was determined by monitoring the incorporation of ^{32}P into the retinoblastoma protein. The reaction consisted of 2.5 ng baculovirus expressed GST-cdk2/cyclin E, 500 ng bacterially produced GST-retinoblastoma protein (aa 776-928), 0.2 mCi ^{32}P g-ATP and 25 mM ATP in kinase buffer (50 mM Hepes, pH 8.0, 10
10 mM MgCl_2 , 5 mM EGTA, 2 mM DTT). The reaction was incubated at 30°C for 30 minutes and then stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15% and incubated on ice for 20 minutes. The reaction was harvested onto GF/C unfilter plates (Packard) using a Packard Filtermate Universal harvester, and
15 the filters were counted on a Packard TopCount 96-well liquid scintillation counter.

cdk 4/cyclin D1 Kinase Activity

 The activity of cdk4/cyclin D1 kinase was determined by
20 monitoring the incorporation of ^{32}P in to the retinoblastoma protein. The reaction consisted of 165 ng baculovirus expressed as GST-cdk4, 282 ng bacterially expressed as S-tag cyclin D1, 500 ng bacterially produced GST-retinoblastoma protein (aa 776-928), 0.2 μCi ^{32}P γ -ATP and 25 μM ATP in kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl_2 , 5 mM EGTA,
25 2 mM DTT). The reaction was incubated at 30°C for 1 hour and then stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15% and incubated on ice for 20 minutes. The reaction was harvested onto GF/C unfilter plates (Packard) using a Packard Filtermate Universal harvester, and the filters were counted on a
30 Packard TopCount 96-well liquid scintillation counter (Coleman, K.G., Wautlet, B.S., Morissey, D, Mulheron, J.G., Sedman, S., Brinkley, P., Price, S., Wedster, K.R. (1997) Identification of CDK4 Sequences involved

in cyclin D, and p16 binding. *J. Biol. Chem.* 272,30:18869-18874, incorporated by reference herein).


Further subject matter of the invention also includes pharmaceuticals for use as described above including controlling
5 cancer, inflammation and arthritis, which contain at least one compound of the formula I as defined above or at least one of its pharmacologically acceptable acid addition salts, and the use of a compound of the formula I as defined above for the preparation of a pharmaceutical having activity against proliferative diseases as
10 described previously including against cancer, inflammation and/or arthritis.

The following examples and preparations describe the manner and process of making and using the invention and are illustrative rather than limiting. It should be understood that there may be many
15 other embodiments which fall within the spirit and scope of the invention as defined by the claims appended hereto.

Example 1

5

(4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,4,6-trifluorophenyl)methanone



10

A. 1-[(4-Methoxyphenyl)methyl]-1H-pyrazol-5-amine

15

To a stirred mixture of 188 g (0.77 mols) of 1-[(4-Methoxyphenyl)methyl]-1H-pyrazol-5-amine hydrochloride in 2 L of methyl t-butyl ether (MTBE) and 1 L of water was added 0.76 L of 1N aq sodium hydroxide solution, the solids dissolved. The aqueous layer was separated and extracted with 1 L of MTBE. The organic layers were combined, washed

20 with 0.5 L of brine, dried (sodium sulfate) and concentrated *in vacuo* to afford 132 g (84%) of compound A as a waxy orange-yellow powder.

25

B. [[[1-[(4-Methoxyphenyl)methyl]-1H-pyrazol-5-yl]amino]methylene]propanedioic acid diethyl ester

30

A mixture of 126 g (0.62 mols) of Part A amine and 140 mL (0.69 mols) of diethyl ethoxymethylenemalonate was heated under reduced pressure with stirring to ~130° under a Dean-Stark apparatus. The

30 reaction mixture was heated for 2.5 h then cooled to room temperature to give 237 g (100%) of compound B as an orange-red oil.

35

C. **4-Hydroxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester**

In a 2 L flask, fitted with a distillation head, 427 g of diphenyl ether was heated to ~235° under nitrogen. To the hot diphenyl ether solution was added a solution of 237 g of crude Part B compound in 250 mL of absolute ethanol over 1 h. The volatile materials (~90 to 120°) were collected through the distillation head while maintaining the pot temperature at ~230°. After 1 h the reaction mixture was cooled to ~45° and 350 mL of methanol was introduced. A thick suspension formed and was allowed to cool to room temperature with mechanical stirring. The resulting mixture was filtered and the solid washed with two-100 mL portions of methanol then 100 mL of heptane. The solid material was allowed to air-dry to afford 122 g (59%) of Part C compound as a fine pale orange powder.

D. **4-Chloro-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester**

20

A mixture of 88.6 g (0.27 mols) of Part C compound in 90 mL of phosphorous oxychloride was heated to ~115° for 50 minutes. The reaction mixture was cooled to room temperature, diluted with 900 mL of dichloromethane then carefully poured onto ~2 kg of crushed ice with stirring. The mixture was diluted with 1 L of dichloromethane and 1 L of water. The aqueous layer was separated and extracted with two-500 mL portions of dichloromethane. The organic layers were combined, dried (sodium sulfate) then filtered through a silica gel plug (~90 g, Merck flash silica) washing with an additional 500 mL of dichloromethane. The filtrate was concentrated *in vacuo* to give 81 g of crude material as a yellow solid. The solid was purified by flash chromatography (Merck silica, ~300 g, 3:1 to 1:1 heptane/ethyl acetate) to afford 61.7 g (66%) of Part D compound as a fine white powder.

E. **4-Butoxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid**

5 To 100 mL (1.1 mols) of 1-butanol was added 1.1 g (48 mmol) of sodium metal piece by piece. The resultant mixture was heated until the sodium was dissolved completely to afford a sodium n-butoxide solution. To the above solution was added a solution of 5.13 g (14.8 mmol) of Part D compound in 100 mL of THF (distilled from ketyl) at room temperature
10 over 20 minutes. The resultant suspension was well stirred at room temperature for 0.5 h and at 60-65° for 3 h. After this time, 0.5 mL (28 mmol) of water was added and the mixture was stirred at 60-65°C for another 3 h. The resultant suspension was concentrated *in vacuo*, acidified with ca 150 mL of 5% aqueous potassium hydrogen sulfate
15 solution to pH = 1 and extracted with three-100 mL portions of methylene chloride. The combined organic extracts were dried (sodium sulfate) and concentrated *in vacuo* to give 5.30 g (100%) of crude Part E as a yellow solid.

20

F. **4-Butoxy-N-methoxy-1-[(4-methoxyphenyl)methyl]-N-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide**

To a suspension of 3.0 g (8.4 mmol) of Part E compound in 75 mL of
25 dry methylene chloride was added 4 drops of DMF and 5.1 mL (2 M solution in methylene chloride, 10 mmol) of oxalyl chloride solution dropwise at room temperature. Gas was evolved during the addition. The resultant solution was stirred at room temperature for 0.5 h and concentrated *in vacuo*. The residue was dissolved in methylene chloride
30 and concentrated *in vacuo* again to afford the acid chloride. To a mixture of the acid chloride and 990 mg (10 mmol) of N,O-dimethylhydroxylamine hydrochloride in 60 mL of methylene chloride was added 3.0 mL (22 mmol) of triethylamine dropwise at 0° with stirring. The mixture was stirred at room temperature for 1 h then

saturated aqueous sodium bicarbonate solution was added until the solution was basic (pH was ca 8). The aqueous layer was separated and extracted with methylene chloride. The combined organic layers were dried (sodium sulfate), concentrated *in vacuo* and purified by flash chromatography (Merck silica, 50 x 200 mm, 1:1 EtOAc/hexanes and then EtOAc) to afford 3.1 g (93%) of Part F compound as a yellow solid.

10 G. **4-Butoxy-N-methoxy-N-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide**

A solution of 1.7 g (4.3 mmol) of Part F compound in 13 mL of trifluoroacetic acid was stirred at 65° for 2.5 h then cooled, concentrated *in vacuo* and neutralized with saturated aqueous sodium bicarbonate solution. The precipitate which formed was collected by filtration, washed with water and then dried. The crude material was dissolved in EtOAc and precipitated by addition of hexanes to afford 1.1 g (89%) of Part G compound as a yellow solid.

20

H. **(4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,4,6-trifluorophenyl)methanone**

To a solution of 2.1 mL (21 mmol) of 1,3,5-trifluorobenzene in 45 mL of THF (distilled from ketyl) was added 12.8 mL (1.6 M solution in hexanes, 20.5 mmol) of n-butyllithium solution dropwise at -78° under argon. The resultant solution was stirred at -78° for 0.5 h and at -45° for 10 minutes. The anion solution was cooled to -78°, then a solution 1.14 g (4.1 mmol) of Part G compound in 25 mL of THF was added dropwise at -78°. The resultant solution was stirred at -78° for 0.5 h and at 0° for 2 h. The reaction was quenched by adding 1 N aqueous hydrochloric acid at 0°C and then neutralized with saturated aqueous sodium bicarbonate solution. The mixture was extracted with EtOAc. The combined extracts were dried (sodium sulfate) and concentrated *in vacuo* to give a solid.

The crude solid was recrystallized (1:1 EtOAc/hexanes) to afford 0.94 g (66%) of the title compound as a yellowish solid, mp 209-211° C.

LC-MS: 350 (M+H)⁺.

5


HPLC: T_R (YMC 4.6x50 mm ODS S-3 MICRON; 2.5 mL/min, gradient 0-100%B over 8 minutes, Buffer A= MeOH/H₂O/H₃PO₄ (10:90:0.2), Buffer B= MeOH/H₂O/H₃PO₄ (90:10:0.2))= 7.2 minutes, > 99% of total peak area at 254 nM.

10

Example 2

(4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,3,5,6-tetrafluoro-4-methylphenyl)methanone

15



20

A. (4-Butoxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,3,5,6-tetrafluoro-4-methylphenyl)methanone

To a mixture of 214 mg (0.60 mmol) of Example 1, Part E compound in 8 mL of dry methylene chloride at room temperature was added a small drop of DMF then 0.36 mL (2M in methylene chloride, 0.72 mmol) of oxalyl chloride solution, gas evolution. After 30 minutes the reaction mixture was concentrated *in vacuo* then additional methylene chloride was added and concentrated again to afford the crude acid chloride. The crude acid chloride was dissolved in 3 mL of THF. A 0.75 mL portion of the acid chloride solution (~0.15 mmol) was removed and added at -78° to a solution of 4-methyl-2,3,5,6-tetrafluorophenyllithium

(0.18 mmol, prepared from n-butyllithium and 1-bromo-4-methyl-2,3,5,6-tetrafluorobenzene in THF at -78°) in 1 mL of THF. The reaction mixture was stirred at -78° for 3 h then at room temperature overnight. The resulting solution was quenched with 1N aqueous HCl solution, neutralized with aqueous saturated sodium bicarbonate and extracted with EtOAc. The organic layer was dried (sodium sulfate) concentrated *in vacuo* and purified by flash chromatography (Merck silica, EtOAc/hexane) to give 22 mg (29%) of Part A compound.

10

B. (4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,4,6-trifluorophenyl)methanone

A solution of 22 mg (0.044 mmol) of Part A compound in 1 mL of TFA was heated to 65° for 2.5 h. The reaction mixture was cooled, concentrated *in vacuo* then added was aqueous sodium bicarbonate. The solid which formed was washed with water, dried under vacuum and recrystallized (EtOAc) to give 5 mg (29%) of the title compound as a white solid.

20

LC-MS: 382 (M+H)+.

HPLC: T_R (Zorbax, SB-C18, 4.6x75 mm; 2.5 mL/min, gradient 0-100%B over 8 minutes, Buffer A= MeOH/H₂O/H₃PO₄ (10:90:0.2), Buffer B= MeOH/H₂O/H₃PO₄ (90:10:0.2))= 8.4 minutes, > 99% of total peak area at 254 nM.

(0.18 mmol, prepared from n-butyllithium and 1-bromo-4-methyl-2,3,5,6-tetrafluorobenzene in THF at -78°) in 1 mL of THF. The reaction mixture was stirred at -78° for 3 h then at room temperature overnight. The resulting solution was quenched with 1N aqueous HCl solution, neutralized with aqueous saturated sodium bicarbonate and extracted with EtOAc. The organic layer was dried (sodium sulfate) concentrated *in vacuo* and purified by flash chromatography (Merck silica, EtOAc/hexane) to give 22 mg (29%) of Part A compound.

10

B. (4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,4,6-trifluorophenyl)methanone

A solution of 22 mg (0.044 mmol) of Part A compound in 1 mL of TFA was heated to 65° for 2.5 h. The reaction mixture was cooled, concentrated *in vacuo* then added was aqueous sodium bicarbonate. The solid which formed was washed with water, dried under vacuum and recrystallized (EtOAc) to give 5 mg (29%) of the title compound as a white solid.


20

LC-MS: 382 (M+H)+.

HPLC: T_R (Zorbax, SB-C18, 4.6x75 mm; 2.5 mL/min, gradient 0-100%B over 8 minutes, Buffer A= MeOH/H₂O/H₃PO₄ (10:90:0.2), Buffer B= MeOH/H₂O/H₃PO₄ (90:10:0.2))= 8.4 minutes, > 99% of total peak area at 254 nM.

Example 3

5 4-Butoxy-N-(2-methylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide



10

To a mixture of 1.00 g (2.8 mmol) of Example 1, Part E compound in 25 mL of dry methylene chloride at room temperature was added 2 small drops of DMF then 1.7 mL (2M in methylene chloride, 3.4 mmol) of oxalyl chloride solution, gas evolution. After 30 minutes the reaction mixture was concentrated *in vacuo* then additional methylene chloride was added and concentrated again to afford the crude acid chloride. The crude acid chloride was dissolved in 10 mL of dichloromethane. A 1 mL portion of the solution of the acid chloride (0.28mmol) was removed and added to a solution of 30 mg (0.40 mmol) of isobutylamine and 81 mg (0.80 mmol) of triethylamine in 1 mL of dichloromethane at 0°. The reaction mixture was warmed to room temperature over 1.5 h then ~1 mL of saturated aqueous sodium bicarbonate was added and extracted with two-1 mL portions of dichloromethane. The combined organic extracts were dried (sodium sulfate) and concentrated *in vacuo* to give a solid.

25 The crude solid was dissolved in 3 mL of TFA and then heated to 65° for 2.5 h. The reaction mixture was cooled, concentrated *in vacuo* then partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The organic phase was separated, dried (sodium sulfate) and concentrated *in vacuo*. The crude material was purified by

30 flash chromatography (Merck silica, 1:19 MeOH/dichloromethane) to afford 71 mg (57%) of the title compound as a light brown solid.


LC-MS: 291 (M+H)+.

HPLC: TR (Zorbax, SB-C18, 4.6x75 mm; 2.5 mL/min, gradient 0-100%B over 8 minutes, Buffer A= MeOH/H₂O/H₃PO₄ (10:90:0.2), Buffer B= MeOH/H₂O/H₃PO₄ (90:10:0.2))= 7.2 minutes, 97% of total peak area at 254 nM.

5

Example 4

10 **[4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone**



15

A. **α -(Ethoxymethylene)- β -oxobenzenepropanoic acid ethyl ester**

A solution of ethylbenzoyl acetate (50 mL, 0.29 mol), triethyl orthoformate (72 mL, 0.43 mol), and acetic anhydride (68 mL, 0.73 mol) was heated at 145 °C under nitrogen for 6 h. After removal of the resulting ethanol under low vacuum, the Part A compound (44%) was isolated by vacuum distillation (3 mm Hg, 165-169 °C) as a brown oil.

20

25 B. **α -[[[1-[(4-Methoxyphenyl)methyl]1H-pyrazol-5-yl]amino]methylene]- β -oxobenzenepropanoic acid ethyl ester**

Example 1, Part A amine hydrochloride (5.0 g, 21 mmol) was suspended in ether (250 mL) and then 10% aqueous K₂CO₃ solution (200 mL) was added. The mixture was stirred at room temperature for 1.5 h and extracted with CH₂Cl₂ (2 x 250 mL). The combined organic layers

30

were concentrated *in vacuo* to give the free amine as a brown oil. The amine was combined with Part A compound (5.3 g, 21 mmol) and heated neat at 120 °C for 1.5 h and then cooled to room temperature. The ethanol by-product was removed *in vacuo* to give Part B compound (9 g, 100%).

5

C. (4-Butoxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,3,5,6-tetrafluoro-4-methylphenyl)methanone

10 Diphenyl ether (50 mL) was heated to 250 °C under nitrogen then a solution of Part B compound (7.0 g, 20 mmol) in 20 mL of diphenyl ether was added dropwise. The temperature was maintained for 1.5 h, after which the solution was cooled to room temperature. The diphenyl ether was removed by distillation (5 mmHg, 93 °C). The pot residue was added
15 to hexane (40 mL) and a yellow precipitate formed. The solid was isolated by vacuum filtration and washed with methanol to give Part C compound (2.5 g, 40%) as a yellow grey solid.

20 D. (4-Chloro-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-5-yl)phenylmethanone

Part C compound (2.4 g, 6.6 mmol) was suspended in 10 mL of POCl₃ then heated to 108 °C for 1.5 h under nitrogen. The reaction
25 mixture was cooled to 0 °C and diluted with CH₂Cl₂ (100 mL). Water (100 mL) was added slowly and the solution was basified to pH 8 with 5N aqueous NaOH solution. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3 x 100 mL). The combined
organic layers were dried (Na₂SO₄) and concentrated *in vacuo* to give a
30 dark oil which was purified by flash chromatography (Merck silica, 230-400 mesh, loaded with CH₂Cl₂, eluted with 1:4 EtOAc/hexane) to give Part D compound (1.5 g, 60%) as a light yellow solid.

E. **[4-(Cyclohexylmethoxy)-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone**


To a solution of cyclohexylmethanol (0.050 mL, 0.41 mmol) and
5 dry CH_2Cl_2 (10 mL, distilled from CaH_2) was added sodium hydride (16
mg, 0.40 mmol) in portions. The reaction mixture was stirred at room
temperature for 15 minutes and then Part D compound (50 mg, 0.13
mmol) was added. After 6 h the reaction was diluted with water (10 mL)
and the organic layer was separated. The aqueous layer was extracted
10 with CH_2Cl_2 (3 x 10 mL). The combined organic layers were dried
(Na_2SO_4) and concentrated *in vacuo* to give Part E compound as an oil
which was used crude in the following reaction.

15 F. **(4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,4,6-trifluorophenyl)methanone**


A mixture of crude Part E compound in TFA (2 mL) was heated at 65
°C for 2.5 h and then cooled to room temperature. The TFA was removed *in*
20 *vacuo* and the remaining residue was dissolved in CH_2Cl_2 (10 mL) and
saturated NaHCO_3 (10 mL) was added. The organic layer was separated
and the aqueous layer was extracted with CH_2Cl_2 (3 x 10 mL). The
combined organic layers were dried (Na_2SO_4) and concentrated *in vacuo* to
give a crude oil which was purified by flash chromatography (Merck silica,
25 230-400 mesh, eluted with 1:19 MeOH/ CH_2Cl_2) to afford the title compound
(35 mg, 80% from Part D compound) as a white solid.

LC-MS: 336 (M+H)⁺.

30 HPLC: T_R (YMC S3 ODS 4.6 x 50 mm; 2.5 mL/min, gradient 0-100%B
over 8 minutes, Buffer A= MeOH/ H_2O / H_3PO_4 (10:90:0.2), Buffer B=
MeOH/ H_2O / H_3PO_4 (90:10:0.2))= 7.7 minutes, >98% of total peak area at 254
nM.

Example 5**5 [4-(Phenylmethoxy)-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone**

To a solution of [4-hydroxy-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone (50 mg, 0.21 mmol) in methanol (1 mL) and saturated aqueous NaHCO₃ solution (10 mL) was added benzyl bromide (0.027 mL, 0.23 mmol). The reaction mixture was stirred at room temperature for 16 h and extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layers were dried (Na₂SO₄) and concentrated in vacuo to give an oil. The crude material was purified by flash chromatography (SiO₂, 230-400 mesh, eluted with 1:19 MeOH / CH₂Cl₂) to afford the title compound (13 mg, 20%) as a white solid.

Example 6**[4-(Butylthio)-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone**

A. **(4-(Butylthio)-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone**

To a solution of 1-butanethiol (0.085 mL, 0.79 mmol) in dry CH₂Cl₂

(10 mL, distilled from CaH_2) was added sodium hydride dispersion (60% in oil, 16 mg, 0.40 mmol) in portions. The reaction mixture was stirred at room temperature for 15 minutes and then Example 4, Part D compound (50 mg, 0.13 mmol) was added. After 6 h the reaction was
5 diluted with water (10 mL) and the organic layer was separated. The aqueous layer was extracted with CH_2Cl_2 (3 x 10 mL). The combined organic layers were dried (Na_2SO_4) and concentrated in vacuo to give Part A compound as an oil which was used crude in the following reaction.

10

B. **[4-(Butylthio)-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone**

Crude Part A compound was dissolved in TFA (2 mL) and the mixture was heated at 65 °C for 2.5 h, then cooled to room temperature.
15 The TFA was removed in vacuo and the remaining residue was dissolved in CH_2Cl_2 (10 mL) and saturated aqueous NaHCO_3 (10 mL) was added. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3 x 10 mL). The combined organic layers were dried (Na_2SO_4) and concentrated in vacuo to give a light yellow solid. The
20 crude material was purified by flash chromatography (SiO_2 , 230-400 mesh, eluted with 1:19 MeOH / CH_2Cl_2) to give the title compound (24 mg, 60%) as a white solid.


LC-MS: 312 (M+H)⁺.

25

HPLC: T_R (YMC S3 ODS 4.6 x 50 mm; 2.5 mL/min, gradient 0-100%B over 8 minutes, Buffer A= MeOH/ H_2O / H_3PO_4 (10:90:0.2), Buffer B= MeOH/ H_2O / H_3PO_4 (90:10:0.2))= 7.7 minutes, >98% of total peak area at 254 nM.

Example 7**[4-(Butylsulfinyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone**

5



10 To Example 6 compound (10 mg, 0.032 mmol) in MeOH (1 ml) and CH_2Cl_2 (0.5 mL) cooled to 0 °C was added a solution of OXONE® (89 mg, 0.15 mmol) in H_2O (1 mL). The reaction mixture was stirred at 0 °C for 15 h and water (10 mL) was added. The aqueous layer was extracted with CH_2Cl_2 (3 x 100 mL). The combined organic layers were dried (Na_2SO_4) and concentrated in vacuo to give yellow solid which was purified by

15 flash chromatography (SiO_2 , 230-400 mesh, loaded with CH_2Cl_2 , eluted with 1:19 MeOH / CH_2Cl_2 to give the title compound (6 mg, 60%) as a yellow solid.


20 LC-MS: 328 ($\text{M}+\text{H}$)⁺.

HPLC: T_R (YMC S3 ODS 4.6 x 50 mm; 2.5 mL/min, gradient 0-100%B over 8 minutes, Buffer A= MeOH/ H_2O / H_3PO_4 (10:90:0.2), Buffer B= MeOH/ H_2O / H_3PO_4 (90:10:0.2))= 7.1 minutes, >98% of total peak area at 254

25 nM.

Example 8**[4-(Butylsulfonyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone**

5



To Example 6 compound (10 mg, 0.032 mmol) in CH_2Cl_2 (10 mL) was added at room temperature m-chloroperoxybenzoic acid (22 mg, 0.13 mmol). The reaction mixture was stirred at room temperature for 1.5 h and then quenched by addition of saturated aqueous NaHCO_3 (10 mL). The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3 x 100 mL). The combined organic layers were dried (Na_2SO_4) and concentrated in vacuo to give a yellow solid which was purified by flash chromatography (SiO_2 , 230-400 mesh, loaded with CH_2Cl_2 , eluted with 1:1 EtOAc / hexane) to give the title compound (5 mg, 50%) as a yellow solid.


20 LC-MS: 344 ($\text{M}+\text{H}$)⁺.

HPLC: T_R (YMC S3 ODS 4.6 x 50 mm; 2.5 mL/min, gradient 0-100%B over 8 minutes, Buffer A= $\text{MeOH}/\text{H}_2\text{O}/\text{H}_3\text{PO}_4$ (10:90:0.2), Buffer B= $\text{MeOH}/\text{H}_2\text{O}/\text{H}_3\text{PO}_4$ (90:10:0.2))= 6.7 minutes, >98% of total peak area at 254 nM.

Claims

5 What is Claimed is:

1. A compound of the formula



10

or pharmaceutically acceptable salts thereof for use as inhibitors of cyclin dependent kinases, wherein:

X is O, S(O)_m;

Y is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl,
15 cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl;

R₁ is hydrogen or lower alkyl;

R₂ is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl,
-O-alkyl, -O-aryl, -NR₄R₅;

20

R₃ is hydrogen or lower alkyl;

R₄ is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl,
cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-
alkyl, -O-aryl;

R₅ is hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl,
25 cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, -O-
alkyl, -O-aryl; and

m is 0, 1 or 2.

2. The compounds as recited in Claim 1, wherein

30

X is oxygen;

Y is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl;

R₁ is hydrogen;

R₂ is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-alkyl, -O-aryl, -NR₄R₅;

5 R₃ is hydrogen;

R₄ is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-alkyl, -O-aryl; and

10 R₅ is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -O-alkyl, -O-aryl.

3. The compounds as recited in Claim 1, wherein

X is oxygen;

15 Y is alkyl, cycloalkyl, or cycloalkylalkyl;

R₁ is hydrogen;

R₂ is aryl or heteroaryl; and

R₃ is hydrogen.

20 4. The compounds as recited in Claim 1, wherein

X is oxygen;

Y is lower alkyl;

R₁ is hydrogen;

R₂ is aryl or heteroaryl; and

25 R₃ is hydrogen.

5. The compounds as recited in Claim 1, wherein

X is oxygen;

Y is lower alkyl;

30 R₁ is hydrogen;

R₂ is 4-bromo-2,6-difluorophenyl, 4-chloro-2,6-difluorophenyl, or 2,4,6-trifluorophenyl; and

R₃ is hydrogen.

35 6. The compounds as recited in Claim 1, wherein

X is S(O)_m;

Y is alkyl or cycloalkyl;
R₁ is hydrogen;
R₂ is aryl or heteroaryl;
R₃ is hydrogen; and
5 m is 0.

7. The compounds as recited in Claim 1, wherein
X is S(O)_m;
Y is lower alkyl;
10 R₁ is hydrogen;
R₂ is aryl or heteroaryl;
R₃ is hydrogen; and
m is 0.

15 8. The compounds as recited in Claim 1, wherein
X is S(O)_m;
Y is lower alkyl;
R₁ is hydrogen;
R₂ is 4-bromo-2,6-difluorophenyl, 4-chloro-2,6-difluorophenyl, or
20 2,4,6-trifluorophenyl;
R₃ is hydrogen; and
m is 0.

9. The compounds as recited in Claim 1, wherein
25 X is S(O)_m;
Y is alkyl or cycloalkyl;
R₁ is hydrogen;
R₂ is aryl or heteroaryl;
R₃ is hydrogen; and
30 m is 1 or 2.

10. The compounds as recited in Claim 1, wherein
X is S(O)_m;
Y is lower alkyl;
35 R₁ is hydrogen;
R₂ is aryl or heteroaryl ;
R₃ is hydrogen; and

m is 1 or 2.

11. The compounds as recited in Claim 1, wherein

X is S(O)_m;

5 Y is lower alkyl;

R₁ is hydrogen;

R₂ is 4-bromo-2,6-difluorophenyl, 4-chloro-2,6-difluorophenyl, or
2,4,6-trifluorophenyl;

R₃ is hydrogen; and

10 m is 1 or 2.

12. The compound as recited in Claim 1, which is

(4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,4,6-trifluorophenyl)

methanone;

15 (4-Butoxy-1H-pyrazolo[3,4-b]pyridin-5-yl)(2,3,5,6-tetrafluoro-4-
methylphenyl)methanone;

4-Butoxy-N-(2-methylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide;

[4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-b]pyridin-5-yl]

20 phenylmethanone;

[4-(Phenylmethoxy)-1H-pyrazolo[3,4-b]pyridin-5-yl]

phenylmethanone;

[4-(Butylthio)-1H-pyrazolo[3,4-b]pyridin-5-yl]phenylmethanone;

[4-(Butylsulfinyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]

25 phenylmethanone; and

[4-(Butylsulfonyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]

phenylmethanone; or

a pharmaceutically acceptable salt thereof.

30 13. A pharmaceutical composition comprising a compound of Claim 1
and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a compound of Claim 1 in combination with a pharmaceutically acceptable carrier, and an anti-cancer agent formulated as a fixed dose.
- 5 15. A pharmaceutical composition according to claim 13 comprising a compound of Claim 1 administered in combination with a pharmaceutically acceptable carrier, with an anticancer treatment or anticancer agent administered in sequence.
- 10 16. The pharmaceutical composition according to Claim 15, wherein said combination comprising said compound of Claim 1 and said pharmaceutically acceptable carrier, is administered prior to administration of said anticancer treatment or anticancer agent.
- 15 17. The pharmaceutical composition according to claim 15, wherein said combination comprising said compound of Claim 1 and said pharmaceutically acceptable carrier, is administered after administration of said anticancer treatment or anticancer agent.
- 20 18. A method of inhibiting protein kinases which comprises administering to a mammalian specie in need thereof an effective protein kinase inhibiting amount of a compound of Claim 1.
- 25 19. A method of inhibiting cyclin dependent kinases which comprises administering to a mammalian specie in need thereof an effective cyclin dependent kinase inhibiting amount of a compound of Claim 1.
- 30 20. A method of inhibiting cdc2 (cdk1) which comprises administering to a mammalian specie in need thereof an effective cdc2 inhibiting amount of a compound of Claim 1.
- 35 21. A method of inhibiting cdk2 which comprises administering to a mammalian specie in need thereof an effective cdk2 inhibiting amount of a compound of Claim 1.

22. A method of inhibiting cdk3 which comprises administering to a mammalian specie in need thereof an effective cdk3 inhibiting amount of a compound of Claim 1.
- 5 23. A method of inhibiting cdk4 which comprises administering to a mammalian specie in need thereof an effective cdk4 inhibiting amount of a compound of Claim 1.
- 10 24. A method of inhibiting cdk5 which comprises administering to a mammalian specie in need thereof an effective cdk5 inhibiting amount of a compound of Claim 1.
- 15 25. A method of inhibiting cdk6 which comprises administering to a mammalian specie in need thereof an effective cdk6 inhibiting amount of a compound of Claim 1.
- 20 26. A method of inhibiting cdk7 which comprises administering to a mammalian specie in need thereof an effective cdk7 inhibiting amount of a compound of Claim 1.
- 25 27. A method of inhibiting cdk8 which comprises administering to a mammalian specie in need thereof an effective cdk8 inhibiting amount of a compound of Claim 1.
28. A method for treating proliferative diseases comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.
- 30 29. A method for treating cancer comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.
- 35 30. A method for treating inflammation, inflammatory bowel disease, or transplantation rejection, comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.

31. A method for treating arthritis comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.

5

32. A method for treating infection by HIV, or for treating and preventing the development of AIDS, comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.

10

33. A method for treating viral infections, comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.

15 34. A method for treating fungal infections, comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.

20 35. A method for preventing the development of cancer or tumor relapse, comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.

25 36. A method for treating neurodegenerative disease, comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 13.

30 37. A method for treating proliferative diseases comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 14.

38. A method for treating cancer comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 14.

39. A method for preventing the development of cancer or tumor relapse, comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 14.

5

40. A method for treating proliferative diseases comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 15.

10 41. A method for treating cancer comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 15.

15 42. A method for preventing the development of cancer or tumor relapse, comprising administering to a mammalian specie in need thereof a therapeutically effective amount of a composition of Claim 15.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/25920

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/44; C07D 471/04

US CL : 514/303; 546/120

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/303; 546/120

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, APS

search terms: cyclin, kinase, cdk

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3,985,757 A (DENZEL et al.) 12 October 1976, columns 1-2, 8-16; columns 17-18, claim 5.	1-4, 6, 7, 9, 10, 13-17, 30, 36
X	US 3,773,778 A (HOEHN et al.) 20 November 1973, columns 1-2; columns 11-12, especially Example 29.	1-17
A, P	US 5,733,920 A (MANSURI et al.) 31 March 1998, columns 1-6.	1-42

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 FEBRUARY 1999

Date of mailing of the international search report

17 MAR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

EVELYN HUANG

Telephone No. (703) 308-1235

THIS PAGE BLANK (USPTO)